Evaluating the Risk of Adverse Events in Patients With Psoriasis Treated With Interleukin Inhibitors Compared With the General Population and Systemic-Naive Patients With Psoriasis

被引：0
|
作者：
Wu, Jashin J. [1 ]
Scotto, Julie [2 ]
Davidson, David [2 ]
Patel, Vardhaman [2 ]
Wei, Zhongyuan [2 ]
Srivastava, Abhishek [3 ]
Potdukhe, Vaishnavi [3 ]
Seigel, Lauren [2 ]
机构：
[1] Univ Miami, Miller Sch Med, Coral Gables, FL USA
[2] Bristol Myers Squibb, New York, NY USA
[3] Mu Sigma, Chicago, IL USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43775
引用
收藏
页码：AB163 / AB163
页数：1
相关论文
共 50 条
  • [1] Serious adverse events in infliximab-treated patients compared with general and psoriasis populations
    Bala, M.
    Diels, J.
    Li, S.
    Gelfand, J. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S61 - S61
  • [2] Serious adverse drug events in inflixitnab-treated patients compared with the general and psoriasis populations
    Gelfand, J. M.
    Diels, J.
    Bala, M.
    Li, S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB5 - AB5
  • [3] Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population
    Sherman, Shany
    Kremer, Noa
    Dalal, Adam
    Solomon-Cohen, Efrat
    Berkovich, Einav
    Noyman, Yehonatan
    Ben-Lassan, Maya
    Levi, Assi
    Pavlovsky, Lev
    Prag Naveh, Hadas
    Hodak, Emmilia
    Amitay-Laish, Iris
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 7
  • [4] Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study
    Strober, Bruce
    Alikhan, Ali
    Lockshin, Benjamin
    Shi, Rebecca
    Cirulli, Joshua
    Schafer, Peter
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 96 (03) : 126 - 133
  • [5] COST-UTILITY ANALYSIS OF INITIAL TREATMENT WITH APREMILAST VERSUS METHOTREXATE IN SYSTEMIC-NAIVE PATIENTS WITH PLAQUE PSORIASIS
    Higa, S.
    Rueda, J.
    Devine, B.
    VALUE IN HEALTH, 2018, 21 : S241 - S241
  • [6] Risk of developing cancer among patients with psoriasis compared with patients without psoriasis
    Gulliver, W.
    Gladney, N.
    Collins, K.
    Morrissey, A.
    MacDonald, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E134 - E134
  • [7] Cytokine effects of apremilast as a mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: results from the UNVEIL trial
    Strober, B.
    Alikhan, M.
    Lockshin, B.
    Schafer, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E256 - E257
  • [8] Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use
    Kaplan, David
    Husni, Elaine
    Chang, Eunice
    S. Broder, Michael
    Paydar, Caleb
    Bognar, Kata
    Yan, Jessie
    Richter, Sven
    Desai, Pooja
    Khilfeh, Ibrahim
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (08) : 575 - 582
  • [9] Perceived quality of life in patients with psoriasis treated with interleukin 17 and 23 inhibitors
    Anguita-Montenegro, Barbara
    Areas-del Aguila, Vera Lucia
    Palacios-Moya, Elena
    Garcia-Arpa, Monica
    Sanchez-Caminero, Maria Prado
    Luque-Jimenez, Maria
    FARMACIA HOSPITALARIA, 2024, 48 (05) : 204 - 211
  • [10] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors
    Anguita-Montenegro, Barbara
    Aguila, Vera Lucia Areas-del
    Palacios-Moya, Elena
    Garcia-Arpa, Monica
    Sanchez-Caminero, Maria Prado
    Luque-Jimenez, Maria
    FARMACIA HOSPITALARIA, 2024, 48 (05) : T204 - T211
12345